No association between a putative functional promoter variant in the dopamine β-hydroxylase gene and schizophrenia

Psychiatric Genetics

Volumn 13, Issue 3, 2003, Pages 175-178

  Jönsson, Erik G ^a   Jamra, Rami Abou ^b   Schumacher, Johannes ^b   Flyckt, Lena ^c   Edman, Gunnar ^d   Forslund, Kaj ^a   Mattila Evenden, Marja ^a   Rylander, Gunnar ^a   Åsberg, Marie ^a   Bjerkenstedt, Lars ^a   Wiesel, Frits Axel ^e   Propping, Peter ^b   Cichon, Sven ^b,f   Nöthen, Markus M ^b,f   Sedvall, Göran C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BONN   (Germany)

^c Jakobsberg Karolinska Psychiat C   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Association; Dopamine hydroxylase gene; Genetics; Schizophrenia

Indexed keywords

DOPAMINE BETA MONOOXYGENASE;

ADULT; AGED; ARTICLE; CATECHOLAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ENZYME LOCALIZATION; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; NORADRENERGIC SYSTEM; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

DOPAMINE BETA-HYDROXYLASE; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; SCHIZOPHRENIA; SWEDEN; VARIATION (GENETICS);

EID: 10744228136     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-200309000-00007     Document Type: Article

References (33)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd revised edition. Washington, DC: American Psychiatric Association; p. 567.
2. Arrufat FJ, Diaz R, Queralt R, Navarro V, Marcos T, Massana G, et al. (2000). Analysis of the polymorphic (GT)n repeat at the dopamine b-hydroxylase gene in Spanish patients affected by schizophrenia. Am J Med Genet 96:88-92.
3. Carlsson A (1978). Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:164-173.
4. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
5. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates.
6. Craig SP, Buckle VJ, Lamouroux A, Mallet J, Craig IW (1988). Localization of the human dopamine beta hydroxylase (DBH) gene to chromosome 9q34. Cytogenet Cell Genet 48:48-50.
7. Erdfelder E, Faul F, Buchner A (1996). GPower: a general power analysis program. Behav Res Methods Instruments Comput 28:1-11.
8. Flyckt L, Sydow O, Bjerkenstedt L, Edman G, Rydin E, Wiesel F-A (1999). Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res 31:113-129.
9. Flyckt LK (2001) Thesis: Schizophrenia as a Systemic Disorder. Studies of Peripheral and Central Biological Functions. Stockholm: Karolinska Institutet.
10. Geijer T, Neiman J, Rydberg U, Gyllander A, Jönsson E, Sedvall G, et al. (1994). Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur Arch Psychiatry Clin Neurosci 244:26-32.
11. Jönsson E (1997) Thesis: Genetic Aspects on Schizophrenia and Cerebrospinal Fluid Monoamine Metabolites. Focus on Association Studies with Candidate Genes. Stockholm: Karolinska Institutet.
12. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, et al. (1999a). Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296.
13. Jönsson EG, Nöthen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, et al. (1999b). Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 40:31-36.
14. Jönsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC (2000). A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 34:239-244.
15. Jönsson EG, Flyckt L, Burgert E, Crocq M-A, Forslund K, Mattila-Evenden M, et al. (2003). Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 13:1-12.
16. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, et al. (1998). NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 81:282-289.
17. Kemper CM, O'Connor DT, Westlund KN (1987). Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neuroscience 23:981-989.
18. Kendler KS, Diehl SR (1993). The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 19:261-285.
19. Meszaros K, Lenzinger E, Füreder T, Hornik K, Willinger U, Stompe T, et al. (1996). Schizophrenia and the dopamine-b-hydroxylase gene: results of a linkage and association study. Psychiatr Genet 6:17-22.
20. Oka K, Kijikawa K, Ohuchi T, Yoshida H, Imaizumi R (1967). Distribution of dopamine-b-hydroxylase activity in subcellular fractions of adrenal medulla. Life Sci 6:461-465.
21. Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G (1986). Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals - a genetic study. J Psychiatr Res 20:19-29.
22. Riley BP, Tahir E, Rajagopalan S, Mogudi-Carter M, Fauré S, Weissenbach J, et al. (1997). A linkage study of the N-methyl-D-aspartate receptor subunit gene loci and schizophrenia in southern African Bantu-speaking families. Psychiatr Genet 7:57-74.
23. Sham PC, Curtis D (1995). Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59:97-105.
24. Spitzer RL, Williams JBW, Gibbon M (1986). Structured Clinical Interview for DSM-III-R - Non Patient Version (SCID-NP). New York: Biometrics Research Department, New York State Psychiatric Institute.
25. van Kammen DP, Kelley M (1991). Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr Res 4:173-191.
26. van Rossum JM (1967). The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB (editors): 5th Collegium Internationale Neuropsychopharmacologicum. Amsterdam: Excerpta Medica; pp. 321-329.
27. Wei J, Ramchand CN, Hemmings GP (1996). A study of relationship between the DBH activity in serum and a Mspl polymorphic site in intron 9 of the human DBH gene in schizophrenia. Schizophr Res 22:77-80.
28. Wei J, Xu H-M, Ramchand C, Hemmings GP (1997). Is the polymorphic microsatellite repeat of the dopamine b-hydroxylase gene associated with biochemical variability of the catecholamine pathway in schizophrenia? Biol Psychiatry 41:762-767.
29. Wei J, Ramchand CN, Hemmings GP (1998). Taql polymorphic sites at the human dopamine beta-hydroxylase gene possibly associated with biochemical alterations of the catecholamine pathway in schizophrenia. Psychiatr Genet 8:19-24.
30. Weinshilboum RM (1983). Biochemical genetics of catecholamines in humans. Mayo Clin Proc 58:319-330.
31. Williams HJ, Bray N, Murphy KC, Cardno AG, Jones LA, Owen MJ (1999). No evidence for allelic association between schizophrenia and a functional variant of the human dopamine beta-hydroxylase gene (DBH). Am J Med Genet 88:557-559.
32. Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet 19:251-253.
33. Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, et al. (2001). A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68:515-522.